GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

Stock Information for GT Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.